BioVoice News April 2017 Issue 11 Volume 1 | Page 45

pharma companies in India and out-license Stempeucel® drug for key indications addressing unmet medical needs and generate significant revenue. Apart from that we also aim to work on globalizing Stempeucel® drug in key markets like US and Europe. For that get necessary regulatory approvals from FDA & EMA. Also, it is important for us to generate significant revenue through Stempeucare® range of cosmetics products in India besides complete Stempeutron™ device development and commercialization in India. Our long term vision is to make the Stempeutics a significant player in the area of stem cells in Asia. KEY MILESTONES FOR STEMPEUTICS SINCE ITS INCEPTION IN 2006 Jan, 2006: Formation of company at Bangalore. R&D of Stempeucel® product May, 2008: Establishment of manufacturing facility at Manipal March, 2009: Phase 1 clinical trial approval granted by DCGI for the treatment of CLI October, 2011: Phase 2 clinical trial approval granted by DCGI for the treatment of CLI December, 2014: Applied for Manufacturing & Marketing Approval in India February, 2015: US Patent Office granting process patent for Stempeucel® product March, 2015: European Medicinal Agency granting ATMP status for Stempeucel® product May, 2015: European Medicinal Agency granting ODD status for Stempeucel® product February, 2016: Limited approval granted by DCGI March, 2017: Manufacturing & Marketing approval granted by DCGI in Form 46 BIOVOICENEWS.COM 45